• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    I

    Ipswich Hospital,Queensland Health,Queensland Government

    EST. 1860
    1,462论文总数
    3.6万引用总数

    Ipswich Hospital is a large district general hospital in Heath Road, Ipswich, Suffolk, England. It is now managed by East Suffolk and North Essex NHS Foundation Trust which was formed on 1 July 2018 by the merging of Ipswich Hospital NHS Trust with Colchester Hospital University NHS Foundation Trust.

    论文量&引用量时间轴

    机构学者

    论文(1462)

    年份
    起
    –
    止
    排序
    1Validation and Longitudinal Trajectory Analysis of an AI-based ECG Model for Aortic Stenosis: from Community Screening to Pre-Tavr Risk Stratification.
    Matthew W Segar, Kaleb D Lambeth,Alexander Postalian, Stephanie Coulter, Jasen Gilge, Naveed Razvi,Mohammad Saeed, Robert D Paisley,Ambarish Pandey,Mehdi Razavi

    Aims:Early aortic stenosis (AS) detection remains challenging, with many patients presenting late when left ventricular dysfunction may be irreversible. We evaluated whether longitudinal AI-enhanced ECG patterns can predict outcomes years before intervention and assessed the community screening potential of the AK-AVS model. Methods and results:We conducted two complementary analyses: (1) community validation of the AK-AVS model in 3632 cardiovascular disease-free ARIC participants, and (2) longitudinal trajectory analysis of 7860 ECGs from 2040 TAVR recipients collected up to 10 years pre-procedure. Unsupervised clustering identified distinct AK-AVS trajectories, with mortality associations assessed using Cox regression and net reclassification improvement. In community screening (n = 16 moderate/severe AS), AK-AVS achieved an AUROC of 0.79, sensitivity 75%, and specificity 75% for moderate/severe AS. At hypothetical screening prevalences of 1-5%, positive predictive values improved to 3.1-14.3%. False-positive predictions identified individuals at 4-fold increased risk for future AS hospitalisation (HR 4.05, P < 0.001) and 52% increased risk for heart failure (HR 1.52, P = 0.02). In the TAVR cohort, trajectory analysis revealed three distinct patterns: Stable Low (19.3%), Accelerated Progression (23.6%), and Persistently High (57.1%). Elevated trajectory groups were older (78.4 and 77.8 vs. 72.6 years, P < 0.001) with higher pacemaker rates (16.4% and 17.3% vs. 10.7%, P = 0.008), despite similar hemodynamic severity. Both elevated patterns independently predicted mortality (Accelerated: HR 1.40, P = 0.03; Persistently High: HR 1.48, P = 0.005) and significantly improved risk reclassification beyond traditional risk scores (NRI 0.069-0.074). Conclusion:Longitudinal AI-ECG trajectory patterns detect disease progression up to 4.5 years before TAVR and enhance mortality prediction beyond traditional risk scores. Community validation shows potential screening utility with 'false-positives' identifying future risk.

    2026European heart journal Digital health(2026)引用:3
    引用
    AI阅读
    加入学术空间
    2Direct Oral Challenge for Penicillin Allergy: the International Network of Antibiotic Allergy Nations (inaan) Study
    Elise A Mitri, Luke R Fletcher,Sara Vogrin,Sara Barnes,Neil Powell,Jonny Peter, Philip H Li,Ana Maria Copaescu, Nicholas A Turner,Fiona James, Camille Paynter, Richard Sullivan,

    BACKGROUND:Approximately 10% of hospitalized patients globally report a penicillin allergy, leading to inappropriate antibiotic prescribing and inferior healthcare outcomes. Evidence supporting the effectiveness and widespread implementation of inpatient penicillin direct oral challenge (DOC) is limited. METHODS:A prospective, multicenter, international type 2 hybrid effectiveness-implementation study was conducted in 40 hospitals across 8 countries between November 2022 and May 2025. Adult inpatients with a penicillin allergy underwent assessment using a digital penicillin allergy toolkit (National Antibiotic Allergy Network [NAAN] App). According to site clinical practice, participants received penicillin DOC (effectiveness intervention) or assessment only. Participating sites received bimonthly audit and feedback at least 3 months after site activation (implementation strategy). Observational data were used to emulate a target trial to examine secondary effectiveness outcomes, including antibiotic prescribing at 90 days in DOC versus non-DOC participants. The primary implementation outcome was adoption of the NAAN App within 6 months of site activation. RESULTS:Among 5121 participants assessed, 1573 (30.7%) underwent DOC, of which 1502 (95.5%) were delabeled. Of 71 (4.5%) participants with a positive DOC, 6 (0.4%) had a serious adverse event. Of 1852 inpatients in the target trial analysis, 892 underwent DOC and 960 underwent assessment only. Participants who underwent DOC were more likely to be prescribed penicillin (risk ratio [RR], 13.25 [95% confidence interval {CI}, 7.82-22.46]), and less likely to be prescribed World Health Organization (WHO) "Watch" or "Reserve" antibiotics (RR, 0.73 [95% CI, .60-.89]) at 90 days post evaluation. Within 6 months of site activation, 77 clinicians adopted the NAAN App. CONCLUSIONS:Multidisciplinary adoption of inpatient penicillin DOC was safe and significantly improved penicillin prescribing and reduced use of WHO restricted antibiotics.

    2026Clinical infectious diseases an official publication of the Infectious Diseases Society of America(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
    Diomidis C Ioannidis, Efthymia Maria Kapasouri, Vassilios S Vassiliou,Eleana Ntatsaki

    Background/Objectives: Janus Kinase inhibitors (JAKi) are an effective treatment option for rheumatoid arthritis (RA); however, emerging concerns regarding cardiovascular and thromboembolic risk have prompted further investigation. We conducted a systematic review and meta-analysis to compare the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in patients receiving JAKi versus other disease-modifying anti-rheumatic drugs (DMARDs). Methods: Following PRISMA 2020 guidelines and a preregistered protocol, we systematically searched PubMed, Embase, and the Cochrane Library. Observational studies and randomized controlled trials (RCTs) reporting MACE or VTE among adults with RA treated with JAKi or comparator DMARDs were included. Hazard ratios (HRs) from observational studies and odds ratios (ORs) from RCTs were pooled using fixed- or random-effects models depending on heterogeneity. A sensitivity analysis was conducted for participants aged ≥ 65 years. Results: Twenty-five observational studies and eight RCTs were included. Across observational studies, the pooled HRs for MACE showed no significant difference between JAKi and other DMARDs, HR = 0.98, 95% CI = 0.85-1.13. This finding remained consistent in individuals aged ≥ 65 years. No increase in MACE risk was observed across RCTs, OR = 1.27, 95% CI = 0.89-1.81. In contrast, JAKi use was associated with a significantly higher risk of VTE in the observational studies (HR = 1.32, 95% CI = 1.08-1.61) but not in the RCTs (OR = 1.69, 95% CI = 0.94-3.02). Conclusions: JAKi use does not appear to increase the risk of MACE compared to DMARDs, including in older adults, but may be associated with a higher risk of VTE. These findings highlight the importance of a personalized approach when considering JAKi therapy, incorporating structured cardiovascular and thrombotic risk assessment, patient preferences, and mitigation of modifiable risk factors.

    2026Journal of personalized medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.
    Ruth E Langley, Duncan C Gilbert, Stephen Mangar, Stuart Rosen, Ellie Bourmaki, Hannah L Rush, Subramaniam Kananga Sundaram,Abdulla Alhasso,Roger Kockelbergh, Hoda Abdel-Aty, Claire L Amos, Louise Brown,

    BACKGROUND:Transdermal estradiol (tE2) is an alternative to luteinizing hormone-releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is suppressed, and the side effects of estrogen depletion due to LHRH agonists and the thromboembolic side effects of oral estrogen are mitigated. METHODS:In this phase 3, noninferiority, randomized trial, we assigned men with locally advanced (M0 and N0 or N+) prostate cancer to receive tE2 patches (100 μg of estradiol every 24 hours) or LHRH agonists. The primary outcome was 3-year metastasis-free survival. The noninferiority margin was 4 percentage points; this corresponded to a target hazard ratio of 1.31, as derived from the observed 3-year metastasis-free survival in the LHRH agonist group. Secondary outcomes included castrate levels of testosterone (<1.7 nmol per liter), overall survival, and safety. RESULTS:Between 2007 and 2022, we recruited 1360 patients at 75 U.K. centers. The median age of the patients was 72 years (interquartile range, 68 to 77); 85% had a T3 tumor stage and 65% an N0 nodal stage. Observed 3-year metastasis-free survival was 87.1% with tE2 and 85.9% with LHRH agonists (hazard ratio for confirmed metastasis or death, 0.96; upper limit of the one-sided 95% confidence interval [CI], 1.11, which met the criterion for noninferiority). Among patients continuing the assigned treatment, castrate levels of testosterone were sustained during the first year after randomization in 85% in each group. Observed 5-year overall survival was 81.1% with tE2 and 79.2% with LHRH agonists (hazard ratio for death, 0.90; 95% CI, 0.75 to 1.07). During treatment, hot flashes occurred in 44% of the patients who received tE2 and 89% of those who received LHRH agonists (grade ≥2 events, 8% and 37%, respectively) and gynecomastia in 85% and 42% (grade ≥2 events, 37% and 9%). CONCLUSIONS:In patients with locally advanced prostate cancer, tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival, with a lower incidence of hot flashes but a higher incidence of gynecomastia. (Funded by Cancer Research U.K. and the U.K. Research Institute Medical Research Council; PATCH ClinicalTrials.gov number, NCT00303784; STAMPEDE-1 ClinicalTrials.gov number, NCT00268476.).

    2026The New England journal of medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): Protocol for an International, Multi-Arm, Multi-Stage, Platform, Randomized Controlled, Double-Blind, Phase 3 Clinical Trial.
    Sean Apap Mangion,Charles Wade,Cheryl Pugh,Matthew Burnell, Rachel Burton, Mary Rauchenberger, Hannah Sweeney, Aoife Nolan, Monica Lewis, Elizabeth Brodnicki, Fleur Hudson,Rachael Hunter,

    Introduction Current treatments for multiple sclerosis (MS) do not address the pathological processes of neurodegeneration and chronic demyelination. This, coupled with the significant challenges of translating promising phase 2 results to phase 3 trial success, highlights the need for more efficient trial designs, such as platform multi-arm multi-stage (MAMS) trial approaches. MAMS trials have demonstrated success in areas such as oncology and infectious diseases. They are typified by a statistically robust core trial design that allows the addition of further treatment arms and utilisation of interim outcome analyses at pre-defined timepoints, to determine whether to terminate a treatment arm early or proceed to the final outcome analysis. To address the challenges in progressive multiple sclerosis (PMS) treatment discovery, the Optimal Clinical Trials Platform for PMS (OCTOPUS) trial was developed. It currently utilises MRI whole-brain atrophy as its interim outcome measure and the clinically relevant composite Expanded Disability Status Scale Plus (EDSS-Plus) as its final outcome measure. A rigorous and systematic drug selection process that assessed preclinical in vitro and animal model evidence, along with additional human data, led to the prioritisation of R/S-alpha lipoic acid (R/S-ALA) and metformin for testing against placebo, targeting pathobiological mechanisms relevant to PMS. All participants will be eligible to receive the current standard of care, including disease-modifying treatments (DMTs). Method and analysis OCTOPUS will be a multi-centre, randomised, placebo-controlled, double-blind, phase 3, MAMS trial of participants aged 25 to 70 years (inclusive) with PMS and an EDSS score of 4.0 to 8.0 (inclusive). Steady progression must be the major cause of increasing disability rather than relapse in the preceding 2 years. In the trial s first candidate drug cycle, participants will be allocated to R/S-ALA, metformin, or placebo in a 1:1:1 ratio. Cycle 1 active treatments will start as R/S-ALA 600 mg once daily, increased after 4 weeks to 600 mg twice daily, or metformin 1 g once daily, increased after 4 weeks to 1 g twice daily. The trial will be multinational, with participation from 28 hospitals across the UK and 10 hospitals in Australia. Clinician-reported measures will include: the EDSS-Plus and the individual components: EDSS, Timed 25 Foot Walk (T25FW); 9 Hole Peg Test (9HPT); Symbol Digit Modalities Test (SDMT); Sloan Low Contrast Visual Acuity (SLCVA); and Relapse assessment. Patient-reported outcomes include MS specific walking, fatigue, pain, and impact scales. We will include a health economic analysis. Analysis stage 1 will require randomisation of 125 participants per arm and utilise MRI percentage brain volume change (PBVC) with the Structural Image Evaluation using Normalisation of Atrophy (SIENA) technique from baseline to 78 weeks. A positive outcome in analysis stage 1 will detect a 0.15% per year whole brain atrophy difference with a one-sided alpha of 0.35 and power of 95%, ensuring a low probability of erroneously rejecting a treatment arm at this stage. Any arms that show a positive effect will proceed to final analysis stage 2. Analysis stage 2 will require 600 participants per arm. Participants included in stage 1 will also be included in the stage 2. Analysis stage 2 will evaluate time to 6-month confirmed disability progression in the EDSS-Plus, in order to detect a 25% hazard ratio reduction with 90% power and an alpha of 0.05. Assuming one treatment arm proceeds to analysis stage 2, the trial will recruit approximately 1,200 participants and last about 6 years. This is approximately two-thirds the size and half the duration of separately conducted two-arm phase 2 and 3 trials. Ethics and dissemination The protocol was approved by the London Hampstead REC (22/LO/0622). This manuscript is based on protocol version 8.0, 28th August 2025. The findings of this trial will be disseminated through peer-reviewed publications and conference presentations. There will be a close communication strategy developed with the UK MS Society (MSS) and full patient and public involvement and engagement (PPIE). Trial registration ISRCTN: 14048364 EudraCT number: 2021-003034-37 CTA 20363/0445 IRAS number: 1003943 Secondary identifying numbers: ND001, CPMS 54274 Strengths and limitations - The OCTOPUS trial will be the first platform multi-arm multi-stage phase 3 trial in PMS, offering the potential to significantly expedite clinical trial processes with advantages in cost- and time-efficiency, focusing specifically on the poorly treated pathobiological processes of chronic neurodegeneration and demyelination - It will begin by assessing two promising drug candidates, immediate-release metformin and R/S-ALA, and will expand over the duration of the trial to include more drug arms under the same trial master protocol - The flexible and statistically robust trial design means that several components of the design (such as the early analysis stage 1 interim outcome) can be updated in line with evolving scientific knowledge - It will ultimately be the largest ever investigator-initiated phase 3 trial in PMS - It will include a range of national and international trial sites, including neuroscience centres and district general hospitals - It will have a high inclusion limit for age (up to 70 years) and disability (up to EDSS 8.0) - Several components (the telephone EDSS and virtual patient-reported outcome measures) will be amenable to remote collection increasing inclusivity and thus addressing public and participant suggestions, while minimising the risk of missing data - The main challenges in this trial design are the statistical and methodological complexity involved in design and implementation, and interpretation of interim trial results. Conclusion The trial launched cycle 1 in January 2023. Analysis stage 1 recruitment of 375 participants was achieved in November 2024, enabling planned interim analysis stage 1 to be conducted by late 2026 (Figure 1). On the 1st of June 2026, in the UK, 24 sites are active with a further 4 in set-up as part of stage 2, and in the Australian extension, Platform Adaptive Trial for Remyelination and Neuroprotection in Multiple Sclerosis (PLATYPUS), 1 site is active, with 9 additional sites in set-up. ### Competing Interest Statement In the last 3 years, JChataway has received support from the Health Technology Assessment (HTA) Programme (National Institute for Health and Care Research, NIHR), the UK MS Society, and the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health and Care Research, University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by MS Canada. A local principal investigator for commercial trials funded by: Ionis and Roche; and has taken part in advisory boards/consultancy for: Biogen, Contineum Therapeutics, FSD Pharma, InnoCare, Pheno Therapeutics and Roche. In the last 5 years ET has received honorarium for consulting work from Biogen, Janssen, Merck, Novartis, and Roche. She has received travel grants to attend or speak at educational meetings from Biogen, Merck, Neuroax, Roche, and Novartis. MP declares institutional educational grant funds or support for medicines from Novartis, Pfizer, Roche, Roche Products, Sanofi, Serum Institute of India, Shionogi, SUMVAX, Synteny Biotechnology, Takeda, Tibotec, Transgene, ViiV Healthcare, Virco Xenothera, CSL Behring, Eli-Lilly, Emergent Biosolutions, Gilead Sciences, GlaxoSmithKline, Grifols, ICON, Janssen Products, Janssen-Cilag, Janssen Pharmaceutica, Johnson & Johnson, Merck Serono, Micronoma, Modus Theraputics, MSD, Mylan, Abcodia, Advanced Accelerator Applications International, Akagera Amgen Aspirin Foundation, Astellas, AstraZeneca, AoA, Baxter, Bayer, Bristol Myers Squibb US, Bri-Bio B&C Group, Cepheid, Cipla, and Clovis JCarpenter reports grants from UK Medical Research Council, personal fees from Wiley, personal fees from Springer, personal fees from University of Bern, personal fees from Statisticians in the Pharmaceutical Industry, and personal fees from Novartis. RH received grants from NIHR DemPRU-QM, NIHR Evidence Synthesis, and NIHR Health Protection Research Unit; received consulting fees from Ministry of Justice, UK Health Security Agency, University of Nottingham, and QuidelOrtho; and leadership role on transforming health and care systems EU funding board as Chair of the Board. AJT receives a fee from being Co-Chair, University College London (UCL)-Eisai Steering Committee drug discovery collaboration; German Aerospace Center, Heath Research (ERA-NET NEURON); consultancy from Sandoz Global Advisory and Novartis. Member, National Multiple Sclerosis Society (USA) Research Programs Advisory Committee; Clinical Trials Committee, Progressive MS Alliance; Board member, European Charcot Foundation; Editor in Chief, Multiple Sclerosis Journal; Editorial Board Member, The Lancet Neurology. AJT has received fees for academic reviews for Jockey Club College at City University of Hong Kong, Health Research Board Ireland, Sant Pau Biomedical Research Institute. AJT has received support from the UCL/ UCLH NIHR Biomedical Research Centre. AJT received travel support from European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the European Charcot Foundation, Health Research Board Emerging Clinical Scientist Award, Polish Neurological Society, and Armin Curt Farewell Symposium. He receives no fee from being Chair (Scientific Ambassadors), Stop MS Appeal Board, UK MS Society; Research and Academic Counsellor, Fundacio Privada Cemcat; Ambassador, European Brain Council. AJT additionally holds a patent for the MSIS-29 Impact Scale. FB is supported by the NIHR biomedical research centre at UCLH. He has been: on the steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai, Prothena and Idorsia; advisory board member for Combinostics, Scottish Brain Sciences, IXICO and Alzheimer Europe; consultant for Roche, Celltrion, Merck, Bracco; research agreements with ADDI, Merck, Biogen, GE Healthcare, Icometrix, Roche; co-founder and shareholder of Queen Square Analytics LTD OC declares being NIHR Research Professor (RP-2017-08- ST2-004); over the past 2 years, member of independent data safety and monitoring board for Novartis; has received consulting fees or speaker honoraria from Lundbeck, Merck or Biogen; contributed to an advisory board for Biogen; she is Deputy Editor of Neurology, for which she receives an honorarium; has received research grant support from the UK MS Society, the NIHR UCLH Biomedical Research Centre, and the NIHR; and is vice-president of ECTRIMS (unpaid). EG is Director of Research at the UK MS Society and has no declarations. CR has received research grants from the UK Medical Research Council, Sanofi, Burden Neurological Society, University of Bristol, and Bristol Health Research Charity, and support for clinical research for the OCTOPUS trial (UK MS Society). CR has participated on a data safety monitoring board for the CCMR Two and NEuEoMS trials. Unpaid advisory roles with the UK MS Society, Burden Neurological Institute, Association of British Neurologists, and NICE HTA Assessment Group. HLF has received honoraria for advisory boards or educational activities from Merck, Novartis, and Roche. HLF has research grant support from the NIHR Health Technology Assessment Programme and Efficacy and Mechanisms Evaluation, UK MS Society, and the Horne Family Charitable Trust. She has been a local PI for multiple sclerosis clinical trials of an investigational medicinal product funded by Novartis, Roche, and Biogen Idec. LF has received honoraria for speaking or as an advisory board member from Biogen, Novartis, Merck, Sanofi Genzyme, and Roche and received support for attending educational meetings from Biogen, Novartis, Merck, Sanofi Genzyme, and Teva. MM has received travel support, speaker honoraria, or consultation fees from Merck-Sereno, Novartis, and Roche. RN receives support from UK MS Society to Imperial College and Swansea university; is a trustee of the Multiple Sclerosis Trials Collaboration charity; and attended paid advisory boards for Novartis and Roche. IG received the following funding in the last 36 months: research grants from Medical Research Council UK, National Institute for Health and Care Research, MS Society UK, Wessex Medical Research, Independent Research Fund Denmark, Rosetrees Trust, Guarantors of Brain, Kedrion, The Binding Site (Part of Thermo Fisher Scientific), and Evgen; speaker honoraria and travel funding from Novartis. D.G. and V.I. are employed by Binding Site (Part of Thermo Fisher Scientific). MBurnell has been funded by grants from the Medical Research Council (MRC), Cancer Research UK, the National Institute for Health Research (NIHR), and The Eve Appeal. RAF has participated on advisory boards, received travel grants and attended educational programmes sponsored by Roche and Novartis. SAB has been awarded funding by the Medical Research Future Fund, MS Australia and the Trish Foundation. He is a principal investigator for a clinical trials sponsored by Novartis and Sanofi, and has received speakers fees from Novartis for chairing scientific meetings. SB has been a principal investigator in clinical trials sponsored by Biogen Idec, Novartis, Genzyme and ATARA Biotherapeutics. ORP has received honoraria and travel expenses from Biogen, Bayer, Genzyme, Merck, Novartis, Roche, Sanofi and Teva and served on advisory boards/acted as a speaker for Biogen, Celgene, Janssen, Merck, Neuraxpharm, Novartis, Roche and Sanofi. SPl is founder, chief scientific officer, and shareholder (>5%) of Cambridge Innovation Technologies Consulting and is a consultant for Aspen Therapeutics, Secretome Therapeutics, Macomics, Solute Guard Therapeutics, and Astex Pharmaceutical. SPa has been funded by grants from the National Institute for Health and Care Research (NIHR) and is a hub lead for the NIHR Leeds Clinical Research Facility. In the last 3 years DF has received research support from the UK MS Society, Higher Education Authority (Rep. of Ireland), Wellcome, Research Ireland and Sangamo Inc. She received consultancy fees for participation in an advisory board for Sangamo Inc. TA has received honoraria or consulting fees for participating in advisory boards related to trial steering committees and data and safety monitoring committees, speaker fees & research grants Janssen, Merck, Novartis, Roche and Sanofi-Genzyme. She is partially funded by the NIHR SCPRA fellowship. All other authors declare no competing interests. ### Clinical Trial ISRCTN: 14048364; EudraCT: 2021-003034-37; CTA: 20363/0445; IRAS: 1003943 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The National Research Ethics Service Committee (London, Hampstead) reviewed the trial protocol and materials to be given to participants (approved 14th October 2022, REC ref 22/LO/0622). The trial protocol and materials to be given to Australian participants has also been reviewed and approved by the Gold Coast Hospital and Health Service, Human Research Ethics Committee (approved 16th December 2024, HREC/2024/QGC/97381). This article refers to the current protocol (Version: 8.0, Date: 28th August 2025). The findings of this trial will be disseminated through peer-reviewed publications and conference presentations. There will be a close communication strategy developed with the United Kingdom Multiple Sclerosis Society and full Patient and Public Involvement Engagement. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes N/A - no data is presented in the current work as it is a protocol paper Multiple Sclerosis Society, https://ror.org/043fwdk81, 135 National Institute for Health and Care Research (NIHR) Research Delivery Network (RDN) MS Australia

    2026引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1462 篇论文

    合作机构(100)

    诺福克和诺维奇大学医院合作论文 83
    昆士兰大学合作论文 56
    阿登布鲁克医院合作论文 55
    剑桥大学合作论文 53
    亚历山大公主医院合作论文 33
    诺丁汉大学合作论文 25
    Royal Brisbane and Women''s Hospital,Queensland Health,Queensland Government合作论文 25
    伊丽莎白女王医院合作论文 25
    James Paget University Hospital,James Paget University Hospitals NHS Foundation Trust合作论文 23
    东英吉利大学合作论文 23

    机构统计